Compare Newmont Corporation (NEM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs BIO-TECHNE Corp — how do they compare? Newmont Corporation trades at $117 (market cap $123.56B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Newmont Corporation is far larger — about 11× BIO-TECHNE Corp's market cap, and Newmont Corporation pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| NEM | TECH | |
|---|---|---|
Market Cap | $123.56B | $11.24B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $72.29 |
52-Week Low | $67.38 | $43.31 |
Enterprise Value | $120.14B | $11.32B |
Dividend Yield | 0.89% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $112.98, up 7.16% over 24 hours, reflecting strong momentum amid record gold prices. The stock exhibits bullish technical signals with moving averages aligned positively, though oscillators suggest overbought conditions. Fundamentally, the company reported robust earnings, with Q2 2026 EPS of $2.10 beating estimates, and annual revenue growth from $11.9B in 2022 to $22.7B in 2025. Recent news highlights a $1.95B settlement with Barrick Mining, resolving Nevada disputes and enhancing strategic flexibility.
Outlook remains positive with a consensus price target of $133, implying 17.8% upside, supported by 75.7% analyst buy ratings. Key opportunities include strong free cash flow generation and production guidance maintenance. Risks involve potential cost pressures in H2 2026, gold price volatility, and insider stock sales by the CEO and CFO in early August 2026.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
